一项评估增生性糖尿病视网膜病变手术中应用纤维蛋白胶止血的初步随机对照试验
该单盲随机对照试验纳入20只因增生性糖尿病视网膜病变(PDR)行玻璃体视网膜手术、术中持续出血点无法电凝止血且无大面积牵拉性视网膜脱离或视网膜裂孔的眼,随机分为常规手术对照组和附加纤维蛋白胶覆盖后部出血点组。结果显示纤维蛋白胶组术后第1周和第4周玻璃体混浊程度均显著低于对照组,且3个月内因玻璃体出血需再次视网膜干预的比例在对照组为5/10、纤维蛋白胶组为0/10。
要点
- 纤维蛋白胶组术后第1周玻璃体混浊平均分级2.4 vs 0.6(对照组 vs 纤维蛋白胶组,P=0.027),第4周2 vs 0(P=0.029)。
- 3个月内因玻璃体出血需再次视网膜干预:对照组5/10,纤维蛋白胶组0/10。
核心结论
- 作者认为,在直视下应用纤维蛋白胶对于预防PDR术后早期复发性玻璃体出血是安全且有效的。
研究设计与样本
- 单盲随机对照临床试验,连续筛查因PDR玻璃体出血行首次玻璃体视网膜手术的患者,最终20只眼随机分为2组。
- 对照组接受常规手术,病例组在常规手术基础上于后部出血部位额外应用纤维蛋白胶。
主要发现
- 两组平均年龄、术前抗血管内皮生长因子注射或视网膜光凝频率、抗血小板药物使用及平均术中血压相似。
- 平均手术时长(54.6 vs 51.6分钟)及纤维增殖>2视盘直径面积的频率(各7只眼)相似;需用镊子和/或剪刀行精细分离者病例组多于对照组(6 vs 3)。
- 每组各有1只眼出现黄斑前膜。
- 术后第1周和第4周玻璃体混浊平均分级对照组均显著高于病例组:第1周2.4 vs 0.6(P=0.027),第4周2 vs 0(P=0.029)。
临床怎么用
- 作者认为,在直视下应用纤维蛋白胶对于预防PDR术后早期复发性玻璃体出血是安全且有效的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and efficacy of fibrin glue in preventing early recurrence of vitreous hemorrhage following surgery for proliferative diabetic retinopathy (PDR). DESIGN: Single-masked randomized controlled clinical trial. SUBJECTS: Consecutive patients with vitreous hemorrhage due to PDR undergoing primary vitreoretinal surgery were screened. After completing all vitreoretinal maneuvers including endocautery to bleeders, infusion pressure was gradually reduced to 5 mm Hg. Eyes with persistent bleeders at the macula and/or the optic nerve head not amenable to endocautery were included. Eyes with tractional retinal detachment more than 5-disc-diameter areas and/or retinal breaks were excluded. METHODS: Twenty eyes were randomized into 2 groups. Controls were treated with conventional surgery, whereas cases were additionally treated with fibrin glue application over the posterior bleeding sites. MAIN OUTCOME MEASURES: Vitreous haze due to early recurrent vitreous hemorrhage was graded at weeks 1 and 4 as the main efficacy outcome measure. Absence of macular membranes at 3 months was the main safety outcome measure. RESULTS: Mean age, frequency of preoperative anti-vascular endothelial growth factor injection or retinal photocoagulation, antiplatelet usage, and mean intraoperative blood pressures were similar between the 2 groups. Mean surgery duration (54.6 vs 51.6 minutes) and frequency of fibrous proliferation >2-disc-diameter areas (7 each) was similar. Fine dissection with forceps and/or scissors was required in more cases than controls (6 vs 3). Macular membranes were noted in 1 participant in each group. Mean grade of vitreous haze was significantly higher in controls than cases at week 1 (2.4 vs 0.6, P = .027) and week 4 (2 vs 0, P = .029). Cases had significantly better odds of having optically clear vitreous cavity at both week 1 (odds ratio [OR] 8.167, CI 1.02-64.03; P = .047) and week 4 (OR 33, CI 1.43-760.67; P = .029). Repeat retinal intervention for vitreous hemorrhage within 3 months was required in 5 of 10 controls, and in none of the cases. CONCLUSION: Our findings indicate fibrin glue application under direct visualization to be safe and efficacious in preventing recurrent vitreous hemorrhage for PDR in the early postoperative period.
引用
- Takkar B, Ketkar MR, Narula R, et al. A Pilot Randomized Controlled Trial Evaluating Hemostasis With Fibrin Glue During Surgery for Proliferative Diabetic Retinopathy. Am J Ophthalmol. 2025. PMID: 39884371. doi:10.1016/j.ajo.2025.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。